Checkmate-141, 2016
NCT02105636 | nivolumab vs standard treatment
in Head and neck cancer | 31/07/2017 00:00:00 | immune checkpoint inhibition for Head and neck cancer in all type of patients |
KEYNOTE-040,
NCT02252042 | pembrolizumab vs standard treatment
in Head and neck cancer | 30/07/2017 00:00:00 | immune checkpoint inhibition for Head and neck cancer in all type of patients |
REVEAL HPS-3 TIMI-55, 2017
NCT01252953 | anacetrapib vs placebo
in cardiovascular prevention | 01/07/2017 00:00:00 | CEPT inhibition for cardiovascular prevention in all type of patients HDL increasing drugs for cardiovascular prevention in all type of patients |
CANTOS, 2017
NCT01327846 | canakinumab vs placebo
in post acute coronary syndromes | 01/07/2017 00:00:00 | anti inflammatory drugs for post acute coronary syndromes in all type of patients anti inflammatory drugs for post myocardial infarction in all type of patients |
CANTOS, 2017
NCT01327846 | canakinumab vs placebo
in post myocardial infarction | 01/07/2017 00:00:00 | anti inflammatory drugs for post acute coronary syndromes in all type of patients anti inflammatory drugs for post myocardial infarction in all type of patients |
| De Jong, | enzastaurin + fulvestrant vs Fulvestrant
in advanced breast cancer (metastatic) | 19/05/2017 00:00:00 | angiogenesis inhibitors for advanced breast cancer (metastatic) in all type of patients |
| LEA, | bevacizumab + endocrine therapy vs endocrine therapy
in advanced breast cancer (metastatic) | 19/05/2017 00:00:00 | angiogenesis inhibitors for advanced breast cancer (metastatic) in all type of patients angiogenesis inhibitors for advanced breast cancer (metastatic) in first line therapy |
| Dickler (CALGB 40503°, 2015 | Letrozole plus bevacizumab vs letrozole
in advanced breast cancer (metastatic) | 19/05/2017 00:00:00 | angiogenesis inhibitors for advanced breast cancer (metastatic) in all type of patients |
Hyams,
NCT00454805 | cediranib + fulvestrant vs fulvestrant
in advanced breast cancer (metastatic) | 19/05/2017 00:00:00 | angiogenesis inhibitors for advanced breast cancer (metastatic) in all type of patients |
Aphinity,
NCT01358877 | pertuzumab vs placebo
in early breast cancer | 05/03/2017 00:00:00 | HER2 inhibitors for early breast cancer in HER2 positive patients |
KEYNOTE-045,
NCT02256436 | pembrolizumab vs investigator’s choice of chemotherapy
in advanced urothelial carcinoma | 18/02/2017 00:00:00 | immune checkpoint inhibition for advanced urothelial carcinoma in all type of patients |
EUCLID, 2016
NCT01732822 | ticagrelor vs clopidogrel
in cardiovascular prevention | 14/11/2016 00:00:00 | antiplatelets drug for cardiovascular prevention in secondary prevention in patients with intermittent claudication antiplatelets drug for peripheral vascular diseases in all type of patient |
EUCLID, 2016
NCT01732822 | ticagrelor vs clopidogrel
in peripheral vascular diseases | 14/11/2016 00:00:00 | antiplatelets drug for cardiovascular prevention in secondary prevention in patients with intermittent claudication antiplatelets drug for peripheral vascular diseases in all type of patient |
AURA 3,
NCT02151981 | Osimertinib vs
in lung cancer (metastatic) | 10/08/2016 00:00:00 | EGFR inhibitors for lung cancer (metastatic) in all type of patients |
IRIS, 2016
NCT00091949 | pioglitazone vs placebo
in diabetes type 2 | 02/05/2016 00:00:00 | glucose lowering for cardiovascular prevention for diabetes type 2 in all type of patients |
GOLD,
NCT01223027 | dovitinib vs sorafenib
in advanced renal-cell carcinoma | 07/12/2015 00:00:00 | All mechanism for advanced renal-cell carcinoma in 2nd line treatment multi target TKI for advanced renal-cell carcinoma in all type of patients |
| Disruptor-1, | BNC105P + everolimus vs everolimus
in advanced renal-cell carcinoma | 07/12/2015 00:00:00 | All mechanism for advanced renal-cell carcinoma in first line multi target TKI for advanced renal-cell carcinoma in all type of patients |
INTORSECT, 2014
NCT00474786 | temsirolimus vs sorafenib
in advanced renal-cell carcinoma | 07/12/2015 00:00:00 | All mechanism for advanced renal-cell carcinoma in 2nd line treatment mTOR inhibitor for advanced renal-cell carcinoma in all type of patients |
| Qin, 2012 | axitinib vs sorafenib
in advanced renal-cell carcinoma | 07/12/2015 00:00:00 | All mechanism for advanced renal-cell carcinoma in first line multi target TKI for advanced renal-cell carcinoma in all type of patients |
SWITCH,
NCT00732914 | sunitinib vs sorafenib
in advanced renal-cell carcinoma | 07/12/2015 00:00:00 | All mechanism for advanced renal-cell carcinoma in first line multi target TKI for advanced renal-cell carcinoma in all type of patients |
RECORD 3, 2014
NCT00903175 | everolimus vs sunitinib
in advanced renal-cell carcinoma | 07/12/2015 00:00:00 | All mechanism for advanced renal-cell carcinoma in first line mTOR inhibitor for advanced renal-cell carcinoma in all type of patients |
| Powles, 2014 | apitolisib vs everolimus
in advanced renal-cell carcinoma | 07/12/2015 00:00:00 | All mechanism for advanced renal-cell carcinoma in first line multi target TKI for advanced renal-cell carcinoma in all type of patients |
VEG105192, 2010
NCT00334282 | pazopanib vs placebo
in advanced renal-cell carcinoma | 07/12/2015 00:00:00 | All mechanism for advanced renal-cell carcinoma in 2nd line treatment multi target TKI for advanced renal-cell carcinoma in all type of patients |
Motzer, 2007
NCT00083889 | sunitinib vs interferon alpha
in advanced renal-cell carcinoma | 05/12/2015 00:00:00 | All mechanism for advanced renal-cell carcinoma in first line multi target TKI for advanced renal-cell carcinoma in all type of patients |
| Escudier, 2009 | sorafenib vs interferon alpha
in advanced renal-cell carcinoma | 05/12/2015 00:00:00 | All mechanism for advanced renal-cell carcinoma in first line multi target TKI for advanced renal-cell carcinoma in all type of patients |
ARCC (Hudes) temsirolimus alone, 2007
NCT00065468 | temsirolimus vs interferon alpha
in advanced renal-cell carcinoma | 05/12/2015 00:00:00 | All mechanism for advanced renal-cell carcinoma in first line mTOR inhibitor for advanced renal-cell carcinoma in all type of patients |
OlympiAD, 2017
NCT02000622 | olaparib vs Physician s choice chemotherapy
in advanced breast cancer (metastatic) | 31/10/2015 00:00:00 | poly ADP-ribose polymerase (PARP) inhibitor for advanced breast cancer (metastatic) in HER 2 negative poly ADP-ribose polymerase (PARP) inhibitor for advanced breast cancer (metastatic) in all type of patients poly ADP-ribose polymerase (PARP) inhibitor for advanced breast cancer (metastatic) in BRCA-mutated |
LEADERS FREE,
NCT01623180 | vs
in percutaneous coronary intervention | 14/10/2015 00:00:00 | bioresorbable vascular scaffold for percutaneous coronary intervention in all type of patients |
ABSORB II,
NCT01425281 | (Absorb, Abbott Vascular, vs everolimus-eluting metallic stent
in percutaneous coronary intervention | 14/10/2015 00:00:00 | bioresorbable vascular scaffold for percutaneous coronary intervention in all type of patients |
| UNLOAD, | vs
in acute heart failure | 13/10/2015 00:00:00 | new drug under development for acute heart failure in all type of patients ultrafiltration for acute heart failure in all type of patients |
